Identification

Name
Cyclobenzaprine
Accession Number
DB00924  (APRD00213)
Type
Small Molecule
Groups
Approved
Description

Cyclobenzaprine is a skeletal muscle relaxant and a central nervous system (CNS) depressant. Cyclobenzaprine acts on the locus coeruleus where it results in increased norepinephrine release, potentially through the gamma fibers which innervate and inhibit the alpha motor neurons in the ventral horn of the spinal cord. It is structurally similar to Amitriptyline, differing by only one double bond.

Structure
Thumb
Synonyms
  • (3-Dibenzo[a,d]cyclohepten-5-ylidene-propyl)-dimethyl-amine
  • Ciclobenzaprina
  • Cyclobenzaprine
  • Cyclobenzaprinum
  • N,N-Dimethyl-5H-dibenzo(a,D)cycloheptene-delta(5,gamma)-propylamine
  • N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Δ5,γ-propylamine
External IDs
TNX-102
Product Ingredients
IngredientUNIICASInChI Key
Cyclobenzaprine Hydrochloride0VE05JYS2P6202-23-9VXEAYBOGHINOKW-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AmrixCapsule, extended release30 mg/1OralRebel Distributors2007-10-01Not applicableUs63459 0701 60 nlmimage10 602d3019
AmrixCapsule, extended release30 mg/1OralCephalon2007-10-01Not applicableUs
AmrixCapsule, extended release30 mg/1OralStat Rx USA2007-10-012018-02-08Us
AmrixCapsule, extended release15 mg/1OralPhysicians Total Care, Inc.2009-04-16Not applicableUs63459 0700 60 nlmimage10 572d2b99
AmrixCapsule, extended release15 mg/1OralA S Medication Solutions2007-10-012017-06-20Us
AmrixCapsule, extended release15 mg/1OralCephalon2007-10-01Not applicableUs
AmrixCapsule, extended release15 mg/1OralStat Rx USA2007-10-012018-02-08Us
AmrixCapsule, extended release30 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2007-10-012017-11-07Us
AmrixCapsule, extended release15 mg/1OralA S Medication Solutions2007-10-02Not applicableUs
AmrixCapsule, extended release15 mg/1OralRebel Distributors2007-10-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-cyclobenzaprine - Tab 10mgTablet10 mgOralAltimed Pharma Inc.1995-12-312005-05-27Canada
Apo-cyclobenzaprineTablet10 mgOralApotex Corporation1995-12-31Not applicableCanada
Auro-cyclobenzaprineTablet10 mgOralAuro Pharma Inc2011-06-15Not applicableCanada
Ava-cyclobenzaprineTablet10 mgOralAvanstra Inc2011-10-112014-08-21Canada
Comfort Pac With CyclobenzaprineKitPd Rx Pharmaceuticals, Inc.2013-07-15Not applicableUs
Cyclo/Gaba 10/300 PackKitOralTmig, Inc.2011-01-29Not applicableUs
CyclobenzaprineTablet, film coated7.5 mg/1OralRising Health Llc2016-10-18Not applicableUs
CyclobenzaprineTablet, film coated5 mg/1OralDirectrx2016-12-16Not applicableUs
Cyclobenzaprine HClTablet, film coated10 mg/1OralOxford Pharmaceuticals, Llc2018-01-25Not applicableUs
Cyclobenzaprine HClTablet, film coated5 mg/1OralOxford Pharmaceuticals, Llc2018-01-25Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Cyclo/MagCyclobenzaprine Hydrochloride + Magnesium oxideKitLiving Well Pharmacy, Inc.2010-03-09Not applicableUs
Cyclo/Mag 10mg/200mgCyclobenzaprine Hydrochloride + Magnesium oxideKitLiving Well Pharmacy, Inc.2010-02-17Not applicableUs
Cyclobenzaprine HydrochlorideCyclobenzaprine Hydrochloride (10 mg/1)Capsule, film coated, extended releaseOralSterling Knight Pharmaceuticals, Llc2016-10-31Not applicableUs
Gapeam BudibacCyclobenzaprine Hydrochloride + Amantadine hydrochloride + Baclofen + Bupivacaine hydrochloride + Diclofenac sodium + Gabapentin + PentoxifyllineKitTopicalAlvix Laboratories2014-12-052018-03-14Us
TabradolCyclobenzaprine HydrochlorideKitOralFusion Pharmaceuticals LLC2009-09-17Not applicableUs
TabradolCyclobenzaprine HydrochlorideKitOralCalifornia Pharmaceuticals, Llc2016-01-01Not applicableUs
Therabenzaprine-60Cyclobenzaprine Hydrochloride + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-05-152016-10-13Us
Therabenzaprine-90Cyclobenzaprine Hydrochloride + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-02-162016-10-13Us
Therabenzaprine-90-5Cyclobenzaprine Hydrochloride + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-02-152016-10-13Us
International/Other Brands
Flexeril (Janssen) / Flexiban (SIT)
Categories
UNII
69O5WQQ5TI
CAS number
303-53-7
Weight
Average: 275.3874
Monoisotopic: 275.167399677
Chemical Formula
C20H21N
InChI Key
JURKNVYFZMSNLP-UHFFFAOYSA-N
InChI
InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3
IUPAC Name
dimethyl(3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-ylidene}propyl)amine
SMILES
CN(C)CCC=C1C2=CC=CC=C2C=CC2=CC=CC=C12

Pharmacology

Indication

For use as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.

Associated Conditions
Pharmacodynamics

Cyclobenzaprine, closely related to the antidepressant amitriptyline, is used as a skeletal muscle relaxant to reduce pain and tenderness and improve mobility. Unlike dantrolene, cyclobenzaprine cannot be used to treat muscle spasm secondary to cerebral or spinal cord disease.

Mechanism of action

Like other tricyclic antidepressants, cyclobenzaprine exhibits anticholinergic activity, potentiation of norepinephrine, and antagonism of reserpine. Cyclobenzaprine does not directly act on the neuromuscular junction or the muscle but relieves muscle spasms through a central action, possibly at the brain stem level. Cyclobenzaprine binds to the serotonin receptor and is considered a 5-HT2 receptor antagonist that reduces muscle tone by decreasing the activity of descending serotonergic neurons.

TargetActionsOrganism
A5-hydroxytryptamine receptor 2A
antagonist
Human
Absorption

Slowly but well absorbed after oral administration

Volume of distribution
Not Available
Protein binding

Very high (93%)

Metabolism

Extensively metabolized (gastrointestinal and hepatic).

Route of elimination

Cyclobenzaprine is extensively metabolized, and is excreted primarily as glucuronides via the kidney.

Half life

18 hours (range 8-37 hours)

Clearance
  • 0.7 L/min
Toxicity

Oral mouse and rat LD50 are 338 mg/kg and 425 mg/kg respectively. Signs of overdose include agitation, coma, confusion, congestive heart failure, convulsions, dilated pupils, disturbed concentration, drowsiness, hallucinations, high or low temperature, increased heartbeats, irregular heart rhythms, muscle stiffness, overactive reflexes, severe low blood pressure, stupor, and vomiting.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineCyclobenzaprine may increase the serotonergic activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbirateroneThe serum concentration of Cyclobenzaprine can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Acetophenazine.Approved
Acetyl sulfisoxazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Cyclobenzaprine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Cyclobenzaprine.Approved, Investigational
AlosetronAlosetron may increase the serotonergic activities of Cyclobenzaprine.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cyclobenzaprine.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Cyclobenzaprine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Cyclobenzaprine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Cyclobenzaprine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Amperozide.Experimental
AmphetamineCyclobenzaprine may increase the serotonergic activities of Amphetamine.Approved, Illicit, Investigational
ApalutamideThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe serum concentration of Cyclobenzaprine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Aripiprazole.Approved, Investigational
ArtemetherThe metabolism of Cyclobenzaprine can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Asenapine.Approved
AtazanavirThe metabolism of Cyclobenzaprine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Cyclobenzaprine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Azaperone.Investigational, Vet Approved
AzelastineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe metabolism of Cyclobenzaprine can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Barbital.Illicit
BenmoxinCyclobenzaprine may increase the serotonergic activities of Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Benzocaine.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Cyclobenzaprine can be decreased when combined with Betaxolol.Approved, Investigational
BifeprunoxThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bifeprunox.Investigational
BoceprevirThe metabolism of Cyclobenzaprine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Cyclobenzaprine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
BrofaromineCyclobenzaprine may increase the serotonergic activities of Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bromazepam.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bupivacaine.Approved, Investigational
BuprenorphineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Cyclobenzaprine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Cyclobenzaprine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cyclobenzaprine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butamben.Approved, Withdrawn
ButaperazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cyclobenzaprine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Cyclobenzaprine.Approved
CaffeineThe metabolism of Cyclobenzaprine can be decreased when combined with Caffeine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Canertinib.Investigational
CarbamazepineThe metabolism of Cyclobenzaprine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cariprazine.Approved, Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Carisoprodol.Approved
CaroxazoneCyclobenzaprine may increase the serotonergic activities of Caroxazone.Withdrawn
CelecoxibThe metabolism of Cyclobenzaprine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cyclobenzaprine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Cyclobenzaprine can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorphenamine.Approved
ChlorproethazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorproethazine.Experimental
ChlorpromazineThe metabolism of Cyclobenzaprine can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Cyclobenzaprine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Cyclobenzaprine can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Cyclobenzaprine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Cyclobenzaprine.Approved
ClarithromycinThe metabolism of Cyclobenzaprine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Cyclobenzaprine can be decreased when combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clidinium.Approved
ClobazamThe metabolism of Cyclobenzaprine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cyclobenzaprine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Cyclobenzaprine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Cyclobenzaprine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Cyclobenzaprine.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Cyclobenzaprine.Approved, Investigational
CrizotinibThe metabolism of Cyclobenzaprine can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Cyclobenzaprine can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cyclizine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Cyclobenzaprine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Cyclobenzaprine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Cyclobenzaprine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Cyclobenzaprine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Cyclobenzaprine.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Cyclobenzaprine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Cyclobenzaprine can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Cyclobenzaprine can be decreased when combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Diphenoxylate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dixyrazine.Experimental
DolasetronDolasetron may increase the serotonergic activities of Cyclobenzaprine.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Cyclobenzaprine can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Doxepin.Approved, Investigational
DoxycyclineThe metabolism of Cyclobenzaprine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved, Illicit
DronedaroneThe metabolism of Cyclobenzaprine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Cyclobenzaprine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Cyclobenzaprine.Approved, Investigational
EliglustatThe metabolism of Cyclobenzaprine can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Enzalutamide.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Cyclobenzaprine.Approved
ErythromycinThe metabolism of Cyclobenzaprine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cyclobenzaprine.Approved, Investigational
EthanolCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyclobenzaprine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fexofenadine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Cyclobenzaprine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cyclobenzaprine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Cyclobenzaprine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Cyclobenzaprine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Cyclobenzaprine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Cyclobenzaprine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Cyclobenzaprine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Cyclobenzaprine can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Frovatriptan.Approved, Investigational
FurazolidoneCyclobenzaprine may increase the serotonergic activities of Furazolidone.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Cyclobenzaprine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Glutethimide.Approved, Illicit
GranisetronGranisetron may increase the serotonergic activities of Cyclobenzaprine.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Cyclobenzaprine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Halothane.Approved, Vet Approved
HarmalineCyclobenzaprine may increase the serotonergic activities of Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Hexobarbital.Approved
HydracarbazineCyclobenzaprine may increase the serotonergic activities of Hydracarbazine.Experimental
HydrocodoneCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclobenzaprine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
IdelalisibThe metabolism of Cyclobenzaprine can be decreased when combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Iloperidone.Approved
ImatinibThe metabolism of Cyclobenzaprine can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Cyclobenzaprine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Cyclobenzaprine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Indiplon.Investigational
IproclozideCyclobenzaprine may increase the serotonergic activities of Iproclozide.Withdrawn
IproniazidCyclobenzaprine may increase the serotonergic activities of Iproniazid.Withdrawn
IsavuconazoleThe serum concentration of Cyclobenzaprine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Cyclobenzaprine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidCyclobenzaprine may increase the serotonergic activities of Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Cyclobenzaprine.Approved, Vet Approved
IsoniazidThe metabolism of Cyclobenzaprine can be decreased when combined with Isoniazid.Approved, Investigational
IsradipineThe metabolism of Cyclobenzaprine can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cyclobenzaprine.Approved
LidocaineThe metabolism of Cyclobenzaprine can be decreased when combined with Lidocaine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Cyclobenzaprine.Approved, Investigational
Lithium cationThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lithium.Experimental
LobeglitazoneThe metabolism of Cyclobenzaprine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Cyclobenzaprine can be increased when used in combination with Lofexidine.Approved, Investigational
LopinavirThe metabolism of Cyclobenzaprine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Cyclobenzaprine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Cyclobenzaprine can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Cyclobenzaprine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cyclobenzaprine.Approved
LuliconazoleThe serum concentration of Cyclobenzaprine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Cyclobenzaprine can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Cyclobenzaprine can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lurasidone.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Cyclobenzaprine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Cyclobenzaprine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Maprotiline.Approved, Investigational
MebanazineCyclobenzaprine may increase the serotonergic activities of Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cyclobenzaprine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Cyclobenzaprine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Cyclobenzaprine.Approved
MethotrimeprazineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methylecgonine.Experimental
Methylene blueCyclobenzaprine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Metoclopramide.Approved, Investigational
MetoprololThe metabolism of Cyclobenzaprine can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineCyclobenzaprine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Cyclobenzaprine can be decreased when combined with Mexiletine.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Cyclobenzaprine.Approved, Illicit
MidostaurinThe metabolism of Cyclobenzaprine can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Cyclobenzaprine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Milnacipran.Approved, Investigational
MinaprineCyclobenzaprine may increase the serotonergic activities of Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved, Investigational
MirabegronThe metabolism of Cyclobenzaprine can be decreased when combined with Mirabegron.Approved
MirtazapineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Mitotane.Approved
MoclobemideCyclobenzaprine may increase the serotonergic activities of Moclobemide.Approved, Investigational
MoclobemideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Moclobemide.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Moperone.Experimental
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Cyclobenzaprine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mosapramine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cyclobenzaprine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Naratriptan.Approved, Investigational
NefazodoneThe metabolism of Cyclobenzaprine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Cyclobenzaprine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Cyclobenzaprine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Cyclobenzaprine can be increased when combined with Nevirapine.Approved
NialamideCyclobenzaprine may increase the serotonergic activities of Nialamide.Withdrawn
NicardipineThe metabolism of Cyclobenzaprine can be decreased when combined with Nicardipine.Approved, Investigational
NilotinibThe metabolism of Cyclobenzaprine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Nitrous oxide.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Cyclobenzaprine.Approved
OctamoxinCyclobenzaprine may increase the serotonergic activities of Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Cyclobenzaprine.Approved, Investigational
OlaparibThe metabolism of Cyclobenzaprine can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Opium.Approved, Illicit
OrphenadrineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cyclobenzaprine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyclobenzaprine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxypertine.Experimental
PalbociclibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Cyclobenzaprine.Approved, Investigational
PanobinostatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineCyclobenzaprine may increase the serotonergic activities of Pargyline.Approved
ParoxetineThe metabolism of Cyclobenzaprine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclobenzaprine.Approved, Vet Approved
PentobarbitalThe metabolism of Cyclobenzaprine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
PerazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Cyclobenzaprine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cyclobenzaprine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Phenazocine.Experimental
PhenelzineCyclobenzaprine may increase the serotonergic activities of Phenelzine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Cyclobenzaprine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Phenibut.Experimental
PheniprazineCyclobenzaprine may increase the serotonergic activities of Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Cyclobenzaprine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Phenoxyethanol.Approved
PhenoxypropazineCyclobenzaprine may increase the serotonergic activities of Phenoxypropazine.Withdrawn
PhenytoinThe metabolism of Cyclobenzaprine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Piritramide.Approved, Investigational
PirlindoleCyclobenzaprine may increase the serotonergic activities of Pirlindole.Approved
PitolisantThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazineCyclobenzaprine may increase the serotonergic activities of Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleCyclobenzaprine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Cyclobenzaprine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Prilocaine.Approved
PrimidoneThe metabolism of Cyclobenzaprine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineCyclobenzaprine may increase the serotonergic activities of Procaine.Approved, Investigational, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineCyclobenzaprine may increase the serotonergic activities of Procarbazine.Approved, Investigational
ProcarbazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyclobenzaprine.Approved, Vet Approved
PromazineThe metabolism of Cyclobenzaprine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Proparacaine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Propericiazine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Cyclobenzaprine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Propoxycaine.Approved
ProthipendylThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cyclobenzaprine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Quetiapine.Approved
QuinidineThe metabolism of Cyclobenzaprine can be decreased when combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Cyclobenzaprine can be decreased when combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Cyclobenzaprine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineCyclobenzaprine may increase the serotonergic activities of Rasagiline.Approved
RasagilineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyclobenzaprine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cyclobenzaprine.Approved, Investigational
RifabutinThe metabolism of Cyclobenzaprine can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Cyclobenzaprine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Cyclobenzaprine can be increased when combined with Rifapentine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Cyclobenzaprine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ritanserin.Investigational
RitonavirThe metabolism of Cyclobenzaprine can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Rizatriptan.Approved
RolapitantThe metabolism of Cyclobenzaprine can be decreased when combined with Rolapitant.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Romifidine.Vet Approved
RopiniroleCyclobenzaprine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ropivacaine.Approved
RotigotineCyclobenzaprine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Cyclobenzaprine can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Cyclobenzaprine.Approved
SafrazineCyclobenzaprine may increase the serotonergic activities of Safrazine.Withdrawn
SaquinavirThe metabolism of Cyclobenzaprine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Cyclobenzaprine can be decreased when used in combination with Sarilumab.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cyclobenzaprine.Approved, Vet Approved
SelegilineCyclobenzaprine may increase the serotonergic activities of Selegiline.Approved, Investigational, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Cyclobenzaprine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
St. John's WortThe serum concentration of Cyclobenzaprine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Cyclobenzaprine can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclobenzaprine.Approved, Investigational
SulfisoxazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Cyclobenzaprine.Approved, Investigational
SuvorexantCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tasimelteon.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Cyclobenzaprine.Approved
TelaprevirThe metabolism of Cyclobenzaprine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Cyclobenzaprine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Cyclobenzaprine.Approved, Investigational
Tenofovir disoproxilThe metabolism of Cyclobenzaprine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbinafineThe metabolism of Cyclobenzaprine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetrodotoxin.Investigational
ThalidomideCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Cyclobenzaprine can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thioproperazine.Approved
ThioridazineThe metabolism of Cyclobenzaprine can be decreased when combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Cyclobenzaprine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tilidine.Experimental
TipranavirThe metabolism of Cyclobenzaprine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tizanidine.Approved, Investigational
TocilizumabThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneCyclobenzaprine may increase the serotonergic activities of Toloxatone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Topiramate.Approved
TramadolCyclobenzaprine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TranylcypromineCyclobenzaprine may increase the serotonergic activities of Tranylcypromine.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cyclobenzaprine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Cyclobenzaprine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Cyclobenzaprine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cyclobenzaprine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Cyclobenzaprine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Triprolidine.Approved
TropisetronTropisetron may increase the serotonergic activities of Cyclobenzaprine.Approved, Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Valproic Acid.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Cyclobenzaprine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Cyclobenzaprine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Veralipride.Experimental
VerapamilThe metabolism of Cyclobenzaprine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Cyclobenzaprine.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Cyclobenzaprine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Cyclobenzaprine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Cyclobenzaprine.Approved, Investigational
ZolpidemCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zotepine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Cyclobenzaprine can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.

References

Synthesis Reference

Villani, F.J.; US. Patent 3,409,640; November 5,1968; assigned to Schering Corporation.

General References
Not Available
External Links
Human Metabolome Database
HMDB0015060
KEGG Compound
C06931
PubChem Compound
2895
PubChem Substance
46508313
ChemSpider
2792
BindingDB
112774
ChEBI
3996
ChEMBL
CHEMBL669
Therapeutic Targets Database
DAP000891
PharmGKB
PA449160
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Cyclobenzaprine
ATC Codes
M03BX08 — Cyclobenzaprine
AHFS Codes
  • 12:20.04 — Centrally Acting Skeletal Muscle Relaxants
FDA label
Download (230 KB)
MSDS
Download (73.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentDriving Impaired1
1CompletedOtherHealthy Volunteers1
1CompletedTreatmentHealthy Adults3
2CompletedTreatmentCervical Strain1
2TerminatedSupportive CarePain / Sleep Initiation and Maintenance Disorders1
3CompletedTreatmentBack Pain / Cervical Pain / Spasms1
3CompletedTreatmentFibromyalgia, Primary1
3Not Yet RecruitingTreatmentLiver Cirrhosis1
3Not Yet RecruitingTreatmentPain, Acute1
3Not Yet RecruitingTreatmentPainful musculoskeletal conditions1
3TerminatedPreventionChronic Migraine1
3TerminatedTreatmentFibromyalgia, Primary1
4CompletedTreatmentPain / Spasms1
4Unknown StatusTreatmentAcute Low Back Pain1
4Unknown StatusTreatmentFibromyalgia / Pain / Sleep / Tiredness1
Not AvailableCompletedNot AvailableAcute Gouty Arthritis / Arthritis / Headaches / Migraines / Muscle Spasms / Radicular syndrome / Synovitis / Tendonitis1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedBasic ScienceUrethral Sphincter Activity1
Not AvailableCompletedTreatmentTemporomandibular Disorders1
Not AvailableUnknown StatusTreatmentPostoperative pain1

Pharmacoeconomics

Manufacturers
  • Anesta ag
  • Actavis totowa llc
  • Aurobindo pharma ltd
  • Cadista pharmaceuticals inc
  • Invagen pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Orit laboratories llc
  • Pliva inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
  • Mcneil pediatrics
Packagers
  • 4uOrtho LLC
  • Advanced Pharmaceutical Services Inc.
  • Aidarex Pharmacuticals LLC
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Apotheca Inc.
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Aurobindo Pharma Ltd.
  • Blenheim Pharmacal
  • Breckenridge Pharmaceuticals
  • Brighton Pharmaceuticals
  • Bryant Ranch Prepack
  • Cadista Pharmaceuticals Inc.
  • Cardinal Health
  • Cephalon Inc.
  • Comprehensive Consultant Services Inc.
  • Corepharma LLC
  • Coupler Enterprises Inc.
  • Dept Health Central Pharmacy
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Dorx LLC
  • ECR Pharmaceuticals
  • Endo Pharmaceuticals Inc.
  • Eurand Pharmaceuticals Inc.
  • Fusion Pharmaceuticals LLC
  • Golden State Medical Supply Inc.
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Innoviant Pharmacy Inc.
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Mckesson Corp.
  • McNeil Laboratories
  • Medisca Inc.
  • Merck & Co.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • Mylan
  • Neighborcare Repackaging Inc.
  • Nucare Pharmaceuticals Inc.
  • Ortho Mcneil Janssen Pharmaceutical Inc.
  • Palmetto Pharmaceuticals Inc.
  • Patient First Corp.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescript Pharmaceuticals
  • Prescription Dispensing Service Inc.
  • Qualitest
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Sandhills Packaging Inc.
  • Sandoz
  • Southwood Pharmaceuticals
  • Spectrum Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Stat Scripts LLC
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • United Research Laboratories Inc.
  • Va Cmop Dallas
  • Vangard Labs Inc.
  • Victory Pharma
  • Vintage Pharmaceuticals Inc.
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
Capsule, extended releaseOral15 mg/1
Capsule, extended releaseOral30 mg/1
Kit
Capsule, film coated, extended releaseOral10 mg/1
Capsule, film coated, extended releaseOral5 mg/1
TabletOral10 mg/1
TabletOral10 mg/10mg
TabletOral5 mg/1
TabletOral7.5 mg/1
Tablet, film coatedOral10 mg/301
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral5 mg/1
Tablet, film coatedOral7.5 mg/1
Kit
KitTopical
TabletOral10 mg
KitOral
Prices
Unit descriptionCostUnit
Cyclobenzaprine hcl crystal273.88USD g
Cyclobenzaprine hcl powder35.84USD g
Fexmid 7.5 mg tablet4.18USD tablet
Flexeril 5 mg tablet2.04USD tablet
Flexeril 10 mg tablet1.74USD tablet
Cyclobenzaprine HCl 5 mg tablet1.71USD tablet
Cyclobenzaprine 5 mg tablet1.64USD tablet
Cyclobenzaprine HCl 10 mg tablet0.47USD tablet
Cyclobenzaprine 10 mg tablet0.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7544372No2003-11-142023-11-14Us
US7829121No2003-11-142023-11-14Us
US7820203No2003-11-142023-11-14Us
US7790199No2003-11-142023-11-14Us
US7387793No2005-02-262025-02-26Us
US9399025No2003-11-142023-11-14Us
US9375410No2003-11-142023-11-14Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
boiling point (°C)173-177Not Available
water solubilityFreely SolubleNot Available
logP5.2Not Available
pKa8.47Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00689 mg/mLALOGPS
logP4.73ALOGPS
logP4.61ChemAxon
logS-4.6ALOGPS
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity102.62 m3·mol-1ChemAxon
Polarizability32.95 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9941
Blood Brain Barrier+0.9512
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7567
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.6447
Renal organic cation transporterInhibitor0.7955
CYP450 2C9 substrateNon-substrate0.7826
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7501
CYP450 1A2 substrateInhibitor0.7324
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8933
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9158
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6955
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8127
BiodegradationNot ready biodegradable0.8727
Rat acute toxicity2.9697 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7531
hERG inhibition (predictor II)Inhibitor0.6767
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene rings connected by a cycloheptene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Dibenzocycloheptenes
Sub Class
Not Available
Direct Parent
Dibenzocycloheptenes
Alternative Parents
Trialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Dibenzocycloheptene / Tertiary aliphatic amine / Tertiary amine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound / Amine / Aromatic homopolycyclic compound
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
organic tricyclic compound (CHEBI:3996)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Honda M, Nishida T, Ono H: Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors. Eur J Pharmacol. 2003 Jan 1;458(1-2):91-9. [PubMed:12498911]
  2. Kobayashi H, Hasegawa Y, Ono H: Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Eur J Pharmacol. 1996 Sep 5;311(1):29-35. [PubMed:8884233]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Wang RW, Liu L, Cheng H: Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91. [PubMed:8818577]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Wang RW, Liu L, Cheng H: Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91. [PubMed:8818577]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8. doi: 10.1124/dmd.104.000794. Epub 2004 Aug 10. [PubMed:15304429]

Drug created on June 13, 2005 07:24 / Updated on July 13, 2018 01:04